Serving To Educate Primary Care Clinicians On Metabolic Issues
Evidence Based Medicine Header 1
Medical Education Header 2
Peer-to-peer Exchange Header 3
Metabolic Diseases Header 4
News: Prescriber's Letter November 2013
Experts will debate whether gliptins (Onglyza, etc) increase cardiovascular risk in patients with type 2 diabetes.
   Gliptins are popular because they're taken orally once a day...and rarely cause hypoglycemia or weight gain.
   In fact, nearly one in four diabetes patients take a gliptin.
   But they cost over $8 a day...and reduce A1C less than 1%.
   Plus there are concerns about possible pancreatitis...and questions now about their cardiovascular safety.
   New evidence shows saxagliptin (Onglyza) and alogliptin (Nesina) don't increase OR decrease ischemic events...even in high-risk patients.  

For the most recent full article AND to access all of the benefits of Prescriber's Letter subscribe to an option below:

Prescriber's Letter offers PCMG Members a 10% discount at two subscription levels:

The Gold Subscription is $129 and includes CME

The Platinum Subscription is $189 and provides enhanced CME and Live Webinar access 

Enter Discount Code PCMG15 when ordering either subscription HERE